Autoimmune Hepatitis Treatment Guidelines
First-Line Treatment Regimen
- The European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines strongly endorse combination therapy with prednisolone (or prednisone) plus azathioprine as the standard first-line treatment for autoimmune hepatitis, achieving remission in 80-90% of patients 1, 2.
- The EASL recommended approach starts with prednisolone 60 mg/day for week 1, tapering weekly, and delaying azathioprine introduction by 2 weeks to avoid diagnostic confusion between azathioprine hepatotoxicity and primary non-response 1.
Treatment Goals and Monitoring
- The therapeutic endpoint is complete normalization of both ALT and IgG levels, not just improvement, but complete normalization 1, 3.
- Persistent elevation of liver enzymes predicts relapse after treatment withdrawal, ongoing histological activity, progression to cirrhosis, and poor outcomes 3.
Maintenance Therapy
- Once remission is achieved, reduce prednisolone to 7.5 mg/day when aminotransferases normalize, and after 3 months, taper to 5 mg/day 1.
- Azathioprine is maintained at 1-2 mg/kg as a steroid-sparing agent 1.
Alternative First-Line Option: Budesonide
- The EASL guidelines acknowledge budesonide as an alternative first-line option for non-cirrhotic patients, particularly those at high risk for steroid side effects 1.
- Budesonide 3 mg three times daily plus azathioprine (1-2 mg/kg/day) achieves normalization of aminotransferases more frequently with fewer side effects compared to standard prednisone regimen at 6 months 4.
Second-Line Therapies
- Mycophenolate mofetil (MMF) is the preferred second-line agent, particularly for azathioprine intolerance rather than refractory disease, with dosing at 1 g daily initially, increasing to maintenance of 1.5-2 g daily 4.
- MMF is effective in 58% of patients with azathioprine intolerance vs only 23% with refractory disease, but is contraindicated in pregnancy due to severe cranial, facial, and cardiac abnormalities reported 4.
Special Clinical Situations
- Acute severe AIH should be treated with high-dose intravenous corticosteroids (≥1 mg/kg) as early as possible, with consideration of liver transplant evaluation for fulminant cases 1, 3.
- AIH-PBC overlap syndrome requires combined therapy with ursodeoxycholic acid (UDCA) 13-15 mg/kg/day plus immunosuppressants, with treatment directed at the predominant disease component 6, 3.
Pregnancy
- Azathioprine requires risk-benefit analysis in pregnancy but may be continued if disease control requires it, while MMF is absolutely contraindicated due to its category D classification 1, 4.
Critical Pitfalls and Caveats
- Azathioprine safety requires checking TPMT levels before initiating to exclude homozygote deficiency, and immediate discontinuation is required if intolerance symptoms emerge 3, 5.
- Non-adherence is a major cause of relapse, particularly in adolescents and young adults, and regular monitoring of immunosuppressant drug levels is indicated 5.